Valuation: Biocorrx Inc

Market Cap 9.59M 8.44M 7.79M 7.28M 13.64M 904M 13.9M 93.57M 36.24M 446M 36M 35.22M 1.55B P/E 2024
-0.78x
P/E 2025 -1.56x
Enterprise Value 11.59M 10.2M 9.41M 8.8M 16.49M 1.09B 16.8M 113M 43.81M 539M 43.51M 42.57M 1.87B EV / Sales 2024
1,004x
EV / Sales 2025 11.4x
Free-Float
38.64%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 58 09/11/2020
President 77 05/01/2024
Director TitleAgeSince
Director/Board Member 58 07/03/2013
Chairman 57 -
Director/Board Member 77 01/03/2019
Change 5-day change 1-year change 3-year change Capi.($)
-15.84%+6.09% - - 9.59M
+2.40%+5.68%+56.55%+48.75% 130B
+0.76%+3.60%+3.88%+31.82% 86.02B
+0.36%+1.68%-4.72%+61.56% 25.63B
+2.25%+5.80%+15.48%+45.92% 22.48B
-0.09%-1.97%-18.15%-26.78% 19.95B
+1.38%+6.95%+9.21%+134.76% 15.76B
+1.38%+3.97%-0.12%+4.66% 14.38B
-0.69%+0.65%+49.09%+115.55% 13.68B
-2.63%-1.04%-14.02%-7.37% 12.86B
Average -1.07%+1.63%+10.80%+45.43% 37.86B
Weighted average by Cap. +1.28%+1.64%+24.01%+43.51%

Financials

2024 2025
Net sales 7.66K 6.75K 6.22K 5.82K 10.91K 722K 11.11K 74.8K 28.97K 356K 28.78K 28.15K 1.24M 797K 702K 647K 606K 1.13M 75.15M 1.16M 7.78M 3.01M 37.07M 2.99M 2.93M 129M
Net income -5.11M -4.5M -4.15M -3.88M -7.27M -481M -7.4M -49.83M -19.3M -237M -19.17M -18.76M -826M -3.44M -3.03M -2.79M -2.61M -4.9M -324M -4.99M -33.57M -13M -160M -12.92M -12.64M -557M
Net Debt 2.72M 2.39M 2.21M 2.06M 3.87M 256M 3.94M 26.53M 10.28M 126M 10.21M 9.98M 440M 2M 1.76M 1.63M 1.52M 2.85M 189M 2.9M 19.53M 7.57M 93.06M 7.51M 7.35M 324M
Logo Biocorrx Inc
BioCorRx Inc. is an addiction treatment solutions company. The Company is engaged in offering treatment for substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app, along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight-loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. It also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary, which is seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.
Employees
-